Alexina J Mason

List of Publications by Year
in descending order

33 papers	**1,726** citations	567281 **15** h-index	434195 **31** g-index
34 all docs	**34** docs citations	**34** times ranked	**2231** citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock. JAMA - Journal of the American Medical Association, 2016, 316, 509.	7.4	456
2	Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. New England Journal of Medicine, 2016, 375, 1638-1648.	27.0	271
3	Effect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients With Vasodilatory Hypotension. JAMA - Journal of the American Medical Association, 2020, 323, 938.	7.4	169
4	Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. Journal of Clinical Investigation, 2014, 124, 3667-3677.	8.2	140
5	The Interaction of Vasopressin and Corticosteroids in Septic Shock. Critical Care Medicine, 2014, 42, 1325-1333.	0.9	106
6	Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Medicine, 2019, 45, 844-855.	8.2	97
7	Effect of a Nurse-Led Preventive Psychological Intervention on Symptoms of Posttraumatic Stress Disorder Among Critically Ill Patients. JAMA - Journal of the American Medical Association, 2019, 321, 665.	7.4	76
8	Long lead-time forecasting of UK air passengers by Holt–Winters methods with damped trend. International Journal of Forecasting, 2001, 17, 71-82.	6.5	74
9	Adjusting for Selection Effects in Epidemiologic Studies. Epidemiology, 2011, 22, 36-39.	2.7	41
10	Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations. PharmacoEconomics - Open, 2017, 1, 79-97.	1.8	40
11	An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial. Trials, 2014, 15, 199.	1.6	36
12	Development of a practical approach to expert elicitation for randomised controlled trials with missing health outcomes: Application to the IMPROVE trial. Clinical Trials, 2017, 14, 357-367.	1.6	33
13	Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial. Intensive Care Medicine, 2019, 45, 1392-1400.	8.2	33
14	Protocol for a randomised controlled trial of VAsopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH). BMJ Open, 2014, 4, e005866-e005866.	1.9	24
15	Permissive versus restrictive temperature thresholds in critically ill children with fever and infection: a multicentre randomized clinical pilot trial. Critical Care, 2019, 23, 69.	5.8	18
16	A full Bayesian model to handle structural ones and missingness in economic evaluations from individual‐level data. Statistics in Medicine, 2019, 38, 1399-1420.	1.6	17
17	Two-pronged Strategy for Using DIC to Compare Selection Models with Non-Ignorable Missing Responses. Bayesian Analysis, 2012, 7, .	3.0	15
18	A Bayesian framework for health economic evaluation in studies with missing data. Health Economics (United Kingdom), 2018, 27, 1670-1683.	1.7	14

#	Article	IF	Citations
19	Are large randomised controlled trials in severe sepsis and septic shock statistically disadvantaged by repeated inadvertent underestimates of required sample size?. BMJ Open, 2018, 8, e020068.	1.9	12
20	Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment. Statistics in Medicine, 2017, 36, 754-771.	1.6	9
21	A framework for extending trial design to facilitate missing data sensitivity analyses. BMC Medical Research Methodology, 2020, 20, 66.	3.1	7
22	Joint Longitudinal Models for Dealing With Missing at Random Data in Trial-Based Economic Evaluations. Value in Health, 2021, 24, 699-706.	0.3	6
23	Different temperature thresholds for antipyretic intervention in critically ill children with fever due to infection: the FEVER feasibility RCT. Health Technology Assessment, 2019, 23, 1-148.	2.8	6
24	Design and analysis features used in small population and rare disease trials: A targeted review. Journal of Clinical Epidemiology, 2022, 144, 93-101.	5.0	6
25	Reduced exposure to vasopressors through permissive hypotension to reduce mortality in critically ill people aged 65 and over: the 65 RCT. Health Technology Assessment, 2021, 25, 1-90.	2.8	4
26	The impact of resuscitation system factors on in-hospital cardiac arrest outcomes across UK hospitals: An observational study. Resuscitation, 2020, 151, 166-172.	3.0	3
27	Levosimendan to prevent acute organ dysfunction in sepsis: the LeoPARDS RCT. Efficacy and Mechanism Evaluation, 2018, 5, 1-94.	0.7	3
28	Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension: Statistical and Health Economic Analysis Plan for the 65 trial. Journal of the Intensive Care Society, 0, , 175114371986038.	2.2	2
29	Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension: Statistical and health economic analysis plan for the 65 trial in article. Journal of the Intensive Care Society, 2020, 21, 230-231.	2.2	2
30	A flexible hierarchical framework for improving inference in area-referenced environmental health studies. Biometrical Journal, 2020, 62, 1650-1669.	1.0	2
31	Flexible Bayesian longitudinal models for cost-effectiveness analyses with informative missing data. Health Economics (United Kingdom), 2021, 30, 3138-3158.	1.7	2
32	A Scoping Review of Item-Level Missing Data in Within-Trial Cost-Effectiveness Analysis. Value in Health, 2022, , .	0.3	2
33	Rejoinder. Clinical Trials, 2017, 14, 370-371.	1.6	0